I'm LongbridgeAI, I can summarize articles.According to the Zhitong Finance APP, BioKangtai (300601.SZ) announced that on August 20, 2020, the company signed a License Agreement with AstraZeneca UK Limited (hereinafter referred to as "AstraZeneca"), granting AstraZeneca exclusive authorization for the company to conduct research and development, production, and commercialization of the ChAdOx1 adenovirus vector COVID-19 vaccine (hereinafter referred to as "licensed product") within the People's Republic of China (excluding Hong Kong Special Administrative Region, Macao Special Administrative Region, and Taiwan).
In light of significant changes in the domestic and international COVID-19 vaccine strains and market environment, both parties have decided to terminate the cooperation on the research and development, production, and commercialization of the licensed product (ChAdOx1 adenovirus vector COVID-19 vaccine) through friendly consultation. Recently, they signed a License Termination Agreement, and all rights and obligations under the original License Agreement will terminate upon the effective date of the License Termination Agreement signed by both parties